| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | VU0155056 | CTRPv2 | pan-cancer | AAC | -0.024 | 0.5 |
| mRNA | PD-0325901 | GDSC1000 | pan-cancer | AAC | 0.021 | 0.5 |
| mRNA | ML320 | CTRPv2 | pan-cancer | AAC | 0.022 | 0.5 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.018 | 0.5 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.037 | 0.5 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.05 | 0.5 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | XMD8-92 | GDSC1000 | pan-cancer | AAC | -0.031 | 0.5 |
| mRNA | Bicalutamide | GDSC1000 | pan-cancer | AAC | -0.021 | 0.5 |
| mRNA | BRD-K27986637 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.5 |